Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study

Frank J. Wolters; Saima Hilal; Maarten J.G. Leening; Maryam Kavousi; Mohsen Ghanbari; the Heart Brain Connection Consortium; Oscar H. Franco; Albert Hofman; Peter J. Koudstaal; Meike W. Vernooij; M. Kamran Ikram; Daniel Bos; M. Arfan Ikram

doi:10.1016/j.atherosclerosis.2022.03.025

Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study

Frank J. Wolters^*, Saima Hilal, Maarten J.G. Leening, Maryam Kavousi, Mohsen Ghanbari, the Heart Brain Connection Consortium, Oscar H. Franco, Albert Hofman, Peter J. Koudstaal, Meike W. Vernooij, M. Kamran Ikram, Daniel Bos, M. Arfan Ikram

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Web of Science)

41 Downloads (Pure)

Abstract

Background and aims:

We aimed to determine associations of plasma amyloid-β40 (Aβ40) with subclinical atherosclerosis and risk of atherosclerotic cardiovascular disease (ASCVD) in the general population.

Methods:

Between 2002 and 2005, plasma Aβ40 was measured by single molecule array (SiMoA®) in 3879 participants of the population-based Rotterdam Study (mean age: 71 years, 61% female). Subclinical atherosclerosis was quantified as computed tomography-assessed calcification volumes. We determined the association of Aβ40 with calcification volumes and clinical ASCVD event risk, and repeated the analyses for ASCVD in a replication cohort of 1467 individuals.

Results:

Higher levels of Aβ40 were associated with increased volumes of calcification in the coronary arteries and to a lesser extent extracranial carotid arteries, independent of traditional cardiovascular risk factors. Of all 3879 participants, 748 developed ASCVD during a median 9.7 years of follow-up. In age- and sex-adjusted models, higher Aβ40 predisposed to a minor increase in ASCVD risk (HR [95%CI]: 1.11[1.02–1.21] per 1-SD increase in Aβ40), driven by coronary heart disease (HR: 1.17[1.05–1.29]) rather than stroke (HR: 1.04[0.93–1.16]). However, excess risk of clinical outcomes was largely explained by baseline differences in cardiovascular risk factors and attenuated after further adjustment (for ASCVD– HR: 1.05[0.96–1.15] and for CHD– HR: 1.08[0.96–1.20]). Results were similar in the replication cohort, with highest risk estimates for CHD (HR: 1.24[1.04–1.48]) in age- and sex-adjusted models, attenuated after adjustment for cardiovascular risk factors (HR: 1.15[0.96–1.39]).

Conclusions:

In this population-based study, higher plasma amyloid-β40 is associated with subclinical atherosclerosis, but not risk of first-ever ASCVD after accounting for traditional cardiovascular risk factors.

Original language	English
Pages (from-to)	44-50
Number of pages	7
Journal	Atherosclerosis
Volume	348
DOIs	https://doi.org/10.1016/j.atherosclerosis.2022.03.025
Publication status	Published - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.atherosclerosis.2022.03.025Licence: CC BY

1-s2.0-S0021915022001587-mainFinal published version, 1.47 MBLicence: CC BY

Cite this

Wolters, F. J., Hilal, S., Leening, M. J. G., Kavousi, M., Ghanbari, M., the Heart Brain Connection Consortium, Franco, O. H., Hofman, A., Koudstaal, P. J., Vernooij, M. W., Ikram, M. K., Bos, D., & Ikram, M. A. (2022). Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study. Atherosclerosis, 348, 44-50. https://doi.org/10.1016/j.atherosclerosis.2022.03.025

@article{d78676a480f24845b700ae4e0ce85c69,

title = "Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study",

abstract = "Background and aims: We aimed to determine associations of plasma amyloid-β40 (Aβ40) with subclinical atherosclerosis and risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Methods: Between 2002 and 2005, plasma Aβ40 was measured by single molecule array (SiMoA{\textregistered}) in 3879 participants of the population-based Rotterdam Study (mean age: 71 years, 61\% female). Subclinical atherosclerosis was quantified as computed tomography-assessed calcification volumes. We determined the association of Aβ40 with calcification volumes and clinical ASCVD event risk, and repeated the analyses for ASCVD in a replication cohort of 1467 individuals. Results: Higher levels of Aβ40 were associated with increased volumes of calcification in the coronary arteries and to a lesser extent extracranial carotid arteries, independent of traditional cardiovascular risk factors. Of all 3879 participants, 748 developed ASCVD during a median 9.7 years of follow-up. In age- and sex-adjusted models, higher Aβ40 predisposed to a minor increase in ASCVD risk (HR [95\%CI]: 1.11[1.02–1.21] per 1-SD increase in Aβ40), driven by coronary heart disease (HR: 1.17[1.05–1.29]) rather than stroke (HR: 1.04[0.93–1.16]). However, excess risk of clinical outcomes was largely explained by baseline differences in cardiovascular risk factors and attenuated after further adjustment (for ASCVD– HR: 1.05[0.96–1.15] and for CHD– HR: 1.08[0.96–1.20]). Results were similar in the replication cohort, with highest risk estimates for CHD (HR: 1.24[1.04–1.48]) in age- and sex-adjusted models, attenuated after adjustment for cardiovascular risk factors (HR: 1.15[0.96–1.39]). Conclusions: In this population-based study, higher plasma amyloid-β40 is associated with subclinical atherosclerosis, but not risk of first-ever ASCVD after accounting for traditional cardiovascular risk factors.",

author = "Wolters, \{Frank J.\} and Saima Hilal and Leening, \{Maarten J.G.\} and Maryam Kavousi and Mohsen Ghanbari and \{the Heart Brain Connection Consortium\} and Franco, \{Oscar H.\} and Albert Hofman and Koudstaal, \{Peter J.\} and Vernooij, \{Meike W.\} and Ikram, \{M. Kamran\} and Daniel Bos and Ikram, \{M. Arfan\}",

year = "2022",

month = may,

doi = "10.1016/j.atherosclerosis.2022.03.025",

language = "English",

volume = "348",

pages = "44--50",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

}

Wolters, FJ, Hilal, S, Leening, MJG , Kavousi, M , Ghanbari, M, the Heart Brain Connection Consortium, Franco, OH, Hofman, A, Koudstaal, PJ , Vernooij, MW , Ikram, MK , Bos, D & Ikram, MA 2022, 'Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study', Atherosclerosis, vol. 348, pp. 44-50. https://doi.org/10.1016/j.atherosclerosis.2022.03.025

TY - JOUR

T1 - Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease

T2 - A population-based study

AU - Wolters, Frank J.

AU - Hilal, Saima

AU - Leening, Maarten J.G.

AU - Kavousi, Maryam

AU - Ghanbari, Mohsen

AU - the Heart Brain Connection Consortium

AU - Franco, Oscar H.

AU - Hofman, Albert

AU - Koudstaal, Peter J.

AU - Vernooij, Meike W.

AU - Ikram, M. Kamran

AU - Bos, Daniel

AU - Ikram, M. Arfan

PY - 2022/5

Y1 - 2022/5

N2 - Background and aims: We aimed to determine associations of plasma amyloid-β40 (Aβ40) with subclinical atherosclerosis and risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Methods: Between 2002 and 2005, plasma Aβ40 was measured by single molecule array (SiMoA®) in 3879 participants of the population-based Rotterdam Study (mean age: 71 years, 61% female). Subclinical atherosclerosis was quantified as computed tomography-assessed calcification volumes. We determined the association of Aβ40 with calcification volumes and clinical ASCVD event risk, and repeated the analyses for ASCVD in a replication cohort of 1467 individuals. Results: Higher levels of Aβ40 were associated with increased volumes of calcification in the coronary arteries and to a lesser extent extracranial carotid arteries, independent of traditional cardiovascular risk factors. Of all 3879 participants, 748 developed ASCVD during a median 9.7 years of follow-up. In age- and sex-adjusted models, higher Aβ40 predisposed to a minor increase in ASCVD risk (HR [95%CI]: 1.11[1.02–1.21] per 1-SD increase in Aβ40), driven by coronary heart disease (HR: 1.17[1.05–1.29]) rather than stroke (HR: 1.04[0.93–1.16]). However, excess risk of clinical outcomes was largely explained by baseline differences in cardiovascular risk factors and attenuated after further adjustment (for ASCVD– HR: 1.05[0.96–1.15] and for CHD– HR: 1.08[0.96–1.20]). Results were similar in the replication cohort, with highest risk estimates for CHD (HR: 1.24[1.04–1.48]) in age- and sex-adjusted models, attenuated after adjustment for cardiovascular risk factors (HR: 1.15[0.96–1.39]). Conclusions: In this population-based study, higher plasma amyloid-β40 is associated with subclinical atherosclerosis, but not risk of first-ever ASCVD after accounting for traditional cardiovascular risk factors.

AB - Background and aims: We aimed to determine associations of plasma amyloid-β40 (Aβ40) with subclinical atherosclerosis and risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Methods: Between 2002 and 2005, plasma Aβ40 was measured by single molecule array (SiMoA®) in 3879 participants of the population-based Rotterdam Study (mean age: 71 years, 61% female). Subclinical atherosclerosis was quantified as computed tomography-assessed calcification volumes. We determined the association of Aβ40 with calcification volumes and clinical ASCVD event risk, and repeated the analyses for ASCVD in a replication cohort of 1467 individuals. Results: Higher levels of Aβ40 were associated with increased volumes of calcification in the coronary arteries and to a lesser extent extracranial carotid arteries, independent of traditional cardiovascular risk factors. Of all 3879 participants, 748 developed ASCVD during a median 9.7 years of follow-up. In age- and sex-adjusted models, higher Aβ40 predisposed to a minor increase in ASCVD risk (HR [95%CI]: 1.11[1.02–1.21] per 1-SD increase in Aβ40), driven by coronary heart disease (HR: 1.17[1.05–1.29]) rather than stroke (HR: 1.04[0.93–1.16]). However, excess risk of clinical outcomes was largely explained by baseline differences in cardiovascular risk factors and attenuated after further adjustment (for ASCVD– HR: 1.05[0.96–1.15] and for CHD– HR: 1.08[0.96–1.20]). Results were similar in the replication cohort, with highest risk estimates for CHD (HR: 1.24[1.04–1.48]) in age- and sex-adjusted models, attenuated after adjustment for cardiovascular risk factors (HR: 1.15[0.96–1.39]). Conclusions: In this population-based study, higher plasma amyloid-β40 is associated with subclinical atherosclerosis, but not risk of first-ever ASCVD after accounting for traditional cardiovascular risk factors.

UR - https://www.scopus.com/pages/publications/85128650913

U2 - 10.1016/j.atherosclerosis.2022.03.025

DO - 10.1016/j.atherosclerosis.2022.03.025

M3 - Article

C2 - 35452865

AN - SCOPUS:85128650913

SN - 0021-9150

VL - 348

SP - 44

EP - 50

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease: A population-based study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this